Search
Research
Infection is the major component of the disease burden in Aboriginal and non-Aboriginal Australian children: a population-based studyInfection accounts for the majority of pediatric mortality and morbidity in developing countries, but there are limited data on the infectious diseases...
Research
Estimating the Impact And Costs of Antimicrobial Resistance (AMR) at Perth Children’s HospitalAMR is a rapidly growing challenge and has been identified as one of the World Health Organizations top 10 global health threats, with the potential to undo many of the health gains observed over the last century.
Research
Evaluating the use and effectiveness of passive immunization in reducing RSV-associated morbidity in high risk infantsHannah Tom Moore Snelling OAM BSc (Hons) GradDipClinEpi PhD BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Diseases Research Head, Infectious
Research
Optimising influenza vaccine uptake in children with medical comorbiditiesChristopher Hannah Blyth Moore MBBS (Hons) DCH FRACP FRCPA PhD OAM BSc (Hons) GradDipClinEpi PhD Centre Head, Wesfarmers Centre of Vaccines and
Research
The PneuCaPTIVE studyChristopher Deborah Blyth Lehmann MBBS (Hons) DCH FRACP FRCPA PhD AO, MBBS, MSc Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases;
Research
PATRIC: Pragmatic Adaptive Trial for Respiratory Infections in ChildrenChristopher Peter Tom Blyth Richmond Snelling MBBS (Hons) DCH FRACP FRCPA PhD MBBS MRCP(UK) FRACP BMBS DTMH GDipClinEpid PhD FRACP Centre Head,
Research
Invasive fungal disease in children with solid tumors: An Australian multicenter 10-year reviewInvasive fungal disease (IFD) occurs less frequently during treatment for solid compared to hematological malignancies in children, and risk groups are poorly defined. Retrospective national multicenter cohort data (2004-2013) were analyzed to document prevalence, clinical characteristics, and microbiology of IFD.
Research
Epidemiology and assessment of Hepatitis B positive children in Western AustraliaTo describe the characteristics of patients with chronic hepatitis B (CHB) presenting to a tertiary paediatric hospital in Perth, Western Australia. Review of implementation of previous follow-up recommendations for the cohort was also undertaken.
Research
Effectiveness of rotavirus vaccines in an Australian population: A case-control studyRV1 and RV5 were both effective in preventing laboratory confirmed and notified rotavirus infections among children aged <5 years
Research
COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statementThe Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19.